Literature DB >> 12922136

Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody.

Donald L Lodmell1, Michael J Parnell, John T Weyhrich, Larry C Ewalt.   

Abstract

Rabid dog exposures cause >99% of human rabies deaths world-wide. In developing countries, where dogs are the viral reservoir, the 30-50% vaccination coverage of dog populations is insufficient to break the disease transmission cycle. In addition, many vaccines currently used in developing countries fail to maintain detectable levels of neutralizing antibody. The poor vaccination coverage with inadequate vaccines, in addition to the difficulty in locating dogs for booster vaccinations, suggest that an inexpensive vaccine that elicits long-term immunity after a single-dose vaccination could improve control of canine rabies in developing countries. One solution could be a DNA vaccine. This study was designed to evaluate in dogs the ability of different methods of a single-dose DNA vaccination to elicit enhanced levels of neutralizing antibody. Intradermal (i.d.) vaccination into ear pinnae elicited elevated and long-lasting levels of neutralizing antibody. Minimal or undetectable levels of neutralizing antibody were detected after vaccination into quadriceps muscle, gene gun vaccination into ear pinnae or i.d. vaccination into the neck. Intramuscular (i.m.) or gene gun vaccinations did not "immunologically prime" a majority of dogs vaccinated by these routes. The passive transfer of sera from dogs that had been vaccinated i.d. in ear pinnae protected mice against rabies virus challenge. A single-dose i.d. rabies DNA vaccination into ear pinnae could aid in the control of canine rabies in developing countries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922136     DOI: 10.1016/s0264-410x(03)00297-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  DNA Vaccine Targeting Gonadotropin-Releasing Hormone Receptor and Its Application in Animal Contraception.

Authors:  Alexandre Samoylov; India Napier; Nancy Morrison; Anna Cochran; Bettina Schemera; James Wright; Russell Cattley; Tatiana Samoylova
Journal:  Mol Biotechnol       Date:  2019-02       Impact factor: 2.695

2.  Enhancement of immunogenicity and efficacy of a plasmid DNA rabies vaccine by nanoformulation with a fourth-generation amine-terminated poly(ether imine) dendrimer.

Authors:  Padinjaremattathil Thankappan Ullas; Shampur Narayan Madhusudana; Anita Desai; Bhadravathi Kenchappa Chandrasekhar Sagar; Govindasamy Jayamurugan; Yamajala Bhaskara Rama Durga Rajesh; Narayanaswami Jayaraman
Journal:  Int J Nanomedicine       Date:  2014-01-28

3.  Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site.

Authors:  Anna Lysén; Ranveig Braathen; Arnar Gudjonsson; Demo Yemane Tesfaye; Bjarne Bogen; Even Fossum
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

4.  High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice.

Authors:  Shadma Ashraf; P K Singh; Dinesh K Yadav; Md Shahnawaz; Satish Mishra; Samir V Sawant; Rakesh Tuli
Journal:  J Biotechnol       Date:  2005-09-22       Impact factor: 3.307

Review 5.  Lyssaviruses: current trends.

Authors:  Susan A Nadin-Davis; Christine Fehlner-Gardiner
Journal:  Adv Virus Res       Date:  2008       Impact factor: 9.937

6.  DNA vaccine constructs against enterovirus 71 elicit immune response in mice.

Authors:  Wong Siew Tung; Sazaly Abu Bakar; Zamberi Sekawi; Rozita Rosli
Journal:  Genet Vaccines Ther       Date:  2007-04-19

7.  Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine.

Authors:  Michal Margalith; Adrián Vilalta
Journal:  Genet Vaccines Ther       Date:  2006-02-15

8.  Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge.

Authors:  Manpreet Kaur; Anant Rai; Rakesh Bhatnagar
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.